FindTrial
Sign In

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02596997
Enrollment
Unknown
Registered
2015-11-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenovirus

Keywords

Adenovirus Brincidofovir

Brief summary

Provide patients with serious AdV infection or disease access to treatment with BCV.

Interventions

DRUGBrincidofovir

Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week

Sponsors

Jazz Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
2 Months to No maximum

Inclusion criteria

* Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids * Able to swallow medication, either tablet or liquid

Exclusion criteria

* Previous dosing with Brincidofovir * If female, not pregnant or trying to become pregnant

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026